INCY - インサイト (Incyte Corporation) インサイト

 INCYのチャート


 INCYの企業情報

symbol INCY
会社名 Incyte Corporation (インサイト)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Commercial Physical_Biological Resarch  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 インサイト(Incyte Corporation)はバイオ医薬品会社であり、治療薬の発見・開発・商品化を主として行う。同社のポートフォリオには、前臨床開発から後期開発までの各段階の化合物、JAKAFI(ルクソリチニブ)およびICLUSIG(ポナチニブ)などの商品化された製品が含まれる。JAKAFI(ルクソリチニブ)は、中間または高リスクの骨髄線維症(MF)を有する患者の治療およびヒドロキシ尿素に不十分な応答または不耐性である真性赤血球増加症(PV)患者の治療に適応される。ICLUSIGの主な標的は、慢性骨髄性白血病およびフィラデルフィア-染色体陽性急性リンパ芽球性白血病で発現される異常なチロシンキナーゼであるB細胞受容体-ABLである。同社はまた、選択的ヤヌス関連キナーゼ1(JAK1)阻害剤のポートフォリオを有している。   インサイトは米国のバイオ医薬品企業。腫瘍学や炎症用に小分子薬剤の開発、商品化を中心に事業を展開。市販品として中間・高リスク骨髄線維症患者の治療薬、JAKAFI(ruxolitinib)を提供。また開発中の薬剤に真性多血症治療薬ruxolitinib、膵臓癌治療薬ruxolitinib、高度な悪性疾患治療薬ruxolitinibなどがある。   Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics.
本社所在地 1801 Augustine Cut-Off Wilmington DE 19803 USA
代表者氏名 Herve Hoppenot Herve Hoppenot
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 302-498-6700
設立年月日 33329
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 1208人
url www.incyte.com
nasdaq_url https://www.nasdaq.com/symbol/incy
adr_tso
EBITDA EBITDA(百万ドル) -42.51400
終値(lastsale) 64.17
時価総額(marketcap) 13641094902.33
時価総額 時価総額(百万ドル) 1442.87
売上高 売上高(百万ドル) 1729.488
企業価値(EV) 企業価値(EV)(百万ドル) 12869.058
当期純利益 当期純利益(百万ドル) -102.32100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Incyte Corporation revenues increased 27% to $903.8M. Net income totaled $11.3M vs. loss of $199.6M. Revenues reflect Product revenues net increase of 26% to $700M Product royalty revenues increase of 62% to $103.7M Milestone revenues increase of 11% to $100M. Net Income reflects Other Research and development decrease of 18% to $445M (expense).

 INCYのテクニカル分析


 INCYのニュース

   Incyte (NASDAQ:INCY) Price Target Cut to $108.00 by Analysts at JMP Securities  2021/11/05 15:50:41 Dakota Financial News
Incyte (NASDAQ:INCY) had its price target decreased by JMP Securities from $124.00 to $108.00 in a report published on Thursday, Price Targets.com reports. JMP Securities currently has a market outperform rating on the biopharmaceutical companys stock. A number of other research analysts have also commented on INCY. Morgan Stanley lowered their price objective on shares []
   Incyte (NASDAQ:INCY) Given New $109.00 Price Target at Oppenheimer  2021/11/05 08:14:41 Dakota Financial News
Incyte (NASDAQ:INCY) had its price target decreased by Oppenheimer from $110.00 to $109.00 in a research report issued to clients and investors on Wednesday, Analyst Price Targets reports. The firm presently has an outperform rating on the biopharmaceutical companys stock. Oppenheimers target price suggests a potential upside of 61.51% from the companys current price. Oppenheimer []
   Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab in Combination with Chemotherapy as First-Line Treatment for Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma  2021/11/04 09:00:00 PR Newswire Asia (English)
SAN FRANCISCO and SUZHOU, China , Nov. 4, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced that the National Medical Products Administration (NMPA) of China has accepted the supplemental New Drug Application (sNDA) for sintilimab in combination with chemotherapy (oxaliplatin and capecitabine) for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. The sNDA application is based on the interim analysis of the randomized, double-blind, multi-center Phase 3 ORIENT-16 clinical trial which evaluated sintilimab in combination with chemotherapy (oxaliplatin and capecitabine), compared to placebo in combination with chemotherapy, for the first-line treatment of unresectable, locally advanced, recurrent or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
   Incyte (NASDAQ:INCY) Reaches New 52-Week Low at $61.98  2021/11/04 08:02:46 Dakota Financial News
Incyte Co. (NASDAQ:INCY)s share price reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $61.98 and last traded at $62.97, with a volume of 32930 shares trading hands. The stock had previously closed at $69.35. A number of equities research analysts have issued reports on the company. []
   Incyte Announces Data from Multiple Programs Within its Oncology Portfolio Accepted for Presentation at the AACR Annual Meeting 2021  2021/03/11 13:00:00 Business Wire
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AACR21--Incyte Announces Data from Multiple Programs Within its Oncology Portfolio Accepted for Presentation at the AACR Annual Meeting 2021.
   Genentech gains clinical development exec by appointing Lilli Petruzzelli; Paul Sekhri caps eventful week, naming Sapna Srivastava CFO of eGenesis  2021/03/05 14:53:10 Endpoints News
→ A spokesperson for Genentech tells Endpoints News that Lilli Petruzzelli has forged a new path this week as SVP, early clinical development at Genentech’s Research and Early Development organization (gRED). Petruzzelli just spent two years as Incyte’s group VP, early clinical development, and prior to Incyte, she was global
   Samenvatting: Incyte kondigt de validatie door het Europees Geneesmiddelenbureau aan van zijn aanvraag voor een vergunning voor het in de handel brengen van Retifanlimab als behandeling voor patiënten met plaveiselcelanaal carcinoom (SCAC)  2021/02/26 14:55:00 Business Wire
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) heeft vandaag de validatie aangekondigd van de Marketing Authorization Application (MAA) van het bedrijf voor retifanlimab, een intraveneuze PD-1-remmer, als een mogelijke behandeling voor volwassen patiënten met lokaal gevorderde of gemetastaseerd plaveiselcelanaalcarcinoom (SCAC) bij wie progressie is opgetreden tijdens of die platina-gebaseerde chemotherapie niet verdraagt. De validatie van de MAA door het Europees Geneesmiddelenbureau
   FXNEWS24 |Biotech Stock Roundup: Regulatory Updates From REGN, INCY, & Other Updates | UK Forex Reviews  2021/02/24 21:53:41 FXNews24
Biotech Stock Roundup: Regulatory Updates From REGN, INCY, & Other Updates | UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News
   Incyte (NASDAQ:INCY) Releases Quarterly Earnings Results  2021/02/10 17:43:53 Transcript Daily
Incyte (NASDAQ:INCY) posted its quarterly earnings results on Monday. The biopharmaceutical company reported $0.93 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.63 by $0.30, Briefing.com reports. The business had revenue of $788.50 million during the quarter, compared to the consensus estimate of $654.08 million. Incyte had a negative net margin of […]
   Genentech gains clinical development exec by appointing Lilli Petruzzelli; Paul Sekhri caps eventful week, naming Sapna Srivastava CFO of eGenesis  2021/03/05 14:53:10 Endpoints News
→ A spokesperson for Genentech tells Endpoints News that Lilli Petruzzelli has forged a new path this week as SVP, early clinical development at Genentech’s Research and Early Development organization (gRED). Petruzzelli just spent two years as Incyte’s group VP, early clinical development, and prior to Incyte, she was global
   Samenvatting: Incyte kondigt de validatie door het Europees Geneesmiddelenbureau aan van zijn aanvraag voor een vergunning voor het in de handel brengen van Retifanlimab als behandeling voor patiënten met plaveiselcelanaal carcinoom (SCAC)  2021/02/26 14:55:00 Business Wire
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) heeft vandaag de validatie aangekondigd van de Marketing Authorization Application (MAA) van het bedrijf voor retifanlimab, een intraveneuze PD-1-remmer, als een mogelijke behandeling voor volwassen patiënten met lokaal gevorderde of gemetastaseerd plaveiselcelanaalcarcinoom (SCAC) bij wie progressie is opgetreden tijdens of die platina-gebaseerde chemotherapie niet verdraagt. De validatie van de MAA door het Europees Geneesmiddelenbureau
   FXNEWS24 |Biotech Stock Roundup: Regulatory Updates From REGN, INCY, & Other Updates | UK Forex Reviews  2021/02/24 21:53:41 FXNews24
Biotech Stock Roundup: Regulatory Updates From REGN, INCY, & Other Updates | UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News
   Incyte (NASDAQ:INCY) Releases Quarterly Earnings Results  2021/02/10 17:43:53 Transcript Daily
Incyte (NASDAQ:INCY) posted its quarterly earnings results on Monday. The biopharmaceutical company reported $0.93 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.63 by $0.30, Briefing.com reports. The business had revenue of $788.50 million during the quarter, compared to the consensus estimate of $654.08 million. Incyte had a negative net margin of […]
   Incyte Reports 2020 Fourth Quarter and Year-End Financial Results, Provides 2021 Financial Guidance and Updates on Key Clinical Programs  2021/02/09 12:00:00 Business Wire
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #earnings--Incyte Reports 2020 Fourth Quarter and Year-End Financial Results, Provides 2021 Financial Guidance and Updates on Key Clinical Programs

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 インサイト INCY Incyte Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)